Inhibition Of PI3K-δ and -γ Isoforms By IPI-145 In Chronic Lymphocytic Leukemia Overcomes Signals From PI3K/AKT/S6 Pathway and Promotes Apoptosis
Balakrishnan K, Peluso M, Fu M, et al.
Key Points:
Preclinical data of IPI-145, potent orally bioavailable compound with PI3K-δ and PI3K-γ inhibitory property, reported in this abstract
IPI-145 induced significant apoptosis in primary CLL cells, accompanied by decreased expression of anti-apoptotic protein Mcl-1
Prognostic markers such as IGHV status, 13q had no impact on sensitivity of CLL cells to compound
IPI-145 was as equipotent as ibrutinib and GS-1101 in promoting apoptosis
It also demonstrated anti-proliferative and anti-migration effects at nanomolar concentrations
Implications:
- Data support further development of this agent in B-cell malignancies, including CLL
View the original abstract on the ASH website.
